Author | Lisette Hilton


Skin of color patients lacking in phase 3 psoriasis trials

September 17, 2020

An overwhelming majority of subjects in phase 3 psoriasis clinical trials are Caucasian, leaving unanswered questions about how one’s ethnicity or race might impact the safety and efficacy of today’s psoriasis treatments, according to a research letter published August 7 in the British Journal of Dermatology.

Tagraxofusp comparable to other chemo regimens as first-line therapy

September 04, 2020

Findings from a recent study support current recommendations to treat patients with BPDCN with tagraxofusp or hyper-CVAD as first-line treatments, then with allogeneic stem cell transplant if patients are eligible.

Tagraxofusp: efficacy, safety and unanswered questions

July 29, 2020

Tagraxofusp, the first and only FDA-approved drug for blastic plasmacytoid dendritic cell neoplasm (BPDCN), outperforms traditional chemotherapy treatment for the rare myeloid malignancy.

Ixekizumab offers quick, lasting relief for genital psoriasis

June 19, 2020

A recent study shows ixekizumab may be able to help treat moderate-to-severe cases of genital psoriasis.

Oral apremilast effectively treats scalp psoriasis

June 19, 2020

A recent article shows oral apremilast may rapidly and significantly improve moderate-to-severe scalp psoriasis.

Topical combination helps clear truncal acne

June 08, 2020

The topical combination of tretinoin 0.05% lotion and azelaic acid 15% foam improved truncal acne and may be an alternative to oral antibiotic treatment, according to recent case studies.

BPDCN patients at increased risk of second primary malignancies

June 01, 2020

Rare aggressive cutaneous lymphoma puts patients at risk of thyroid and non-lymphocytic leukemia second primary malignancies, researchers say.

Glycolic-salicylic acid serum safe, effective

May 28, 2020

The authors of a recently published commentary report they’ve developed a glycolic and salicylic acid combination serum they say could disrupt traditional use of topical benzoyl peroxide and antibiotics to treat acne.

Ruxolitinib data positive for efficacy, safety

May 22, 2020

Ruxolitinib met primary and secondary endpoints in the phase 3 TRueE-AD1 and TRuE-AD2 studies, underscoring the idea that the disruption of multiple cytokine networks simultaneously is a promising treatment approach.

In search of a better way to assess itch

May 22, 2020

Researchers evaluating several itch assessment tools say there is a need for a better way. Studies comparing the validity and reliability of itch measurement scales are lacking, say researchers who examined several available assessment tools.